MedTrace Logo

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-04-01

No results posted yet for this study

Summary

The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).

Conditions

  • Nonsmall Cell Lung Cancer
  • Nonsmall Cell Lung Cancer, Stage II
  • Nonsmall Cell Lung Cancer Stage III
  • Unresectable Non-Small Cell Lung Carcinoma

Interventions

RADIATION

Genomically Guided Radiation Therapy (RT)

Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.

Sponsors & Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Thomas Dilling, MD · Moffitt Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2023-11-29
Completion
2024-08-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873439 on ClinicalTrials.gov